Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23840
Title: Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.
Austin Authors: Srinivasan, Ashish ;De Cruz, Peter P ;van Langenberg, Daniel R
Affiliation: Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia
Gastroenterology and Hepatology
Medicine (University of Melbourne)
Department of Medicine, Monash University, Melbourne, Victoria, Australia
Issue Date: Aug-2020
Publication information: Alimentary Pharmacology & Therapeutics 2020; 52(3): 561-562
URI: http://ahro.austin.org.au/austinjspui/handle/1/23840
DOI: 10.1111/apt.15862
ORCID: 0000-0001-5952-1570
0000-0003-3662-6307
PubMed URL: 32656826
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Apr 17, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.